Want to see AU:LDX full AI Analyst Report?
LDX Stock Chart & Stats
AU$0.32
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.32
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.33
Previous CloseN/A
Volume213.94K
Average Volume (3M)1.40M
Market Cap
AU$94.51M
Enterprise ValueAU$85.46
Total Cash (Recent Filing)AU$15.42M
Total Debt (Recent Filing)AU$5.94M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Mar 04, 2027Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding945,123,840
10 Day Avg. Volume962,654
30 Day Avg. Volume1,402,598
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.59
Price to Sales (P/S)4.38
P/FCF Ratio-37.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside-21.88% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$29.93M
Bulls Say, Bears Say
Bulls Say
Long-term U.S. Distribution Growth OpportunityThe exclusive PHASE agreement provides a multi-year commercial pathway for FebriDx, improving market access and revenue visibility. Its minimum sales commitment could support scale, customer adoption and manufacturing utilisation if regulatory clearance is obtained.
Reimbursement And Market ExpansionSecured reimbursement strengthens the economic case for physician-office adoption and reduces a key commercial barrier. Broader reimbursement coverage can support durable demand for FebriDx and improve the potential returns from the company’s U.S. distribution strategy.
Product Traction And Margin ImprovementRapid product revenue growth and a high reported gross margin indicate improving commercial traction and potentially attractive economics for FebriDx. Sustained product mix improvement could help offset weaker services and IP revenue over the medium term.
Bears Say
Persistent UnprofitabilityContinued operating and net losses show that the business has not yet achieved sustainable profitability. The FY2026 negative gross profit is especially concerning because it raises questions about product economics, accounting impacts and the durability of future margins.
Negative Free Cash Flow And Funding NeedsThe company remains unable to consistently fund investment and other cash requirements internally. Ongoing negative free cash flow, a USD 1.0 million facility draw and expected capacity investment increase dependence on financing or future operating improvements.
Commercial Ramp Depends On Regulatory ApprovalUntil the CLIA waiver is granted, FebriDx remains restricted from broader marketing in the CLIA-waived setting. This creates execution and timing risk for the distribution agreement, reimbursement opportunity, revenue ramp and planned manufacturing scale-up.
Lumos Diagnostics Holdings Ltd. News
LDX FAQ
What was Lumos Diagnostics Holdings Ltd.’s price range in the past 12 months?
Lumos Diagnostics Holdings Ltd. lowest share price was AU$0.08 and its highest was AU$0.33 in the past 12 months.
What is Lumos Diagnostics Holdings Ltd.’s market cap?
Lumos Diagnostics Holdings Ltd.’s market cap is AU$94.51M.
When is Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date?
Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 181 days.
How were Lumos Diagnostics Holdings Ltd.’s earnings last quarter?
Lumos Diagnostics Holdings Ltd. released its earnings results on Aug 25, 2026. The company reported AU$0 earnings per share for the quarter, beating the consensus estimate of -AU$0.014 by AU$0.014.
Is Lumos Diagnostics Holdings Ltd. overvalued?
According to Wall Street analysts Lumos Diagnostics Holdings Ltd.’s price is currently Overvalued.
Does Lumos Diagnostics Holdings Ltd. pay dividends?
Lumos Diagnostics Holdings Ltd. does not currently pay dividends.
What is Lumos Diagnostics Holdings Ltd.’s EPS estimate?
Lumos Diagnostics Holdings Ltd.’s EPS estimate is 0.
How many shares outstanding does Lumos Diagnostics Holdings Ltd. have?
Lumos Diagnostics Holdings Ltd. has 945,123,840 shares outstanding.
What happened to Lumos Diagnostics Holdings Ltd.’s price movement after its last earnings report?
Lumos Diagnostics Holdings Ltd. reported an EPS of AU$0 in its last earnings report, beating expectations of -AU$0.014. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Lumos Diagnostics Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:LDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lumos Diagnostics Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.25 (-21.88% Downside)
AU$0.25 (-21.88% Downside)
Blogger Sentiment
Bullish
AU:LDX Sentiment 92%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$82.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
85.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. (LDX) is a diagnostics company focused on developing and commercialising point-of-care (rapid) diagnostic tests, including antigen-based tests that use immunoassay technologies. The company operates in the in-vitro diagnostics sector and targets applications such as infectious disease and other rapid testing settings, supplying test products and related diagnostic solutions to healthcare and other testing markets.
LDX Stock 12 Month Forecast
Average Price Target
AU$0.25
▼(-21.88% Downside)
Technical Analysis
―
BCAL Diagnostics Limited
―
Genetic Signatures Ltd.
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―







